Generic placeholder image

Current Drug Targets

Author(s): Ling Wang, Qi Wang, Yangchun Xu, Manhua Cui and Liying Han*

DOI: 10.2174/1389450120666190925123507

DownloadDownload PDF Flyer Cite As
Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance

Page: [167 - 178] Pages: 12

  • * (Excluding Mailing and Handling)

Abstract

The standard treatment for advanced ovarian cancer is cytoreductive surgery followed by cytotoxic chemotherapy. However, it has high risk of recurrence and poor prognosis. Poly(ADPribose) polymerase (PARP) inhibitors selectively target DNA double-strand breaks (DSBs) in tumor cells that cannot be repaired and induce the synthetic lethality of BRCA1/2 mutation cancers. PARP inhibitors are clinically used to treat recurrent ovarian cancer and show significant efficacy in ovarian cancer patients with homologous recombination repair (HRR) pathway defects. PARP inhibitors also have significant clinical benefits in patients without HR defects. With the increasingly extensive clinical application of PARP inhibitors, the possibility of acquiring drug resistance is high. Therefore, clinical strategies should be adopted to manage drug resistance of PARP inhibitors. This study aims to summarize the indications and toxicity of PARP inhibitors, the mechanism of action, targeted treatment of drug resistance, and potential methods to manage drug-resistant diseases. We used the term “ovarian cancer” and the names of each PARP inhibitor as keywords to search articles published in the Medical Subject Headings (MeSH) on Pubmed, along with the keywords “clinicaltrials.gov” and “google.com/patents” as well as “uspto.gov.” The FDA has approved olaparib, niraparib, and rucaparib for the treatment of recurrent epithelial ovarian cancer (EOC). Talazoparib and veliparib are currently in early trials and show promising clinical results. The mechanism underlying resistance to PARP inhibitors and the clinical strategies to overcome them remain unclear. Understanding the mechanism of resistance to PARP inhibitors and their relationship with platinum resistance may help with the development of antiresistance therapies and optimization of the sequence of drug application in the future clinical treatment of ovarian cancer.

Keywords: PARP inhibitors, ovarian cancer, targeted treatment, toxicity, drug resistance mechanism, MeSH.

Graphical Abstract

[1]
Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: A review. Cancer Biol Med 2017; 14(1): 9-32.
[http://dx.doi.org/10.20892/j.issn.2095-3941.2016.0084] [PMID: 28443200]
[2]
Madariaga A, Lheureux S, Oza AM. Tailoring ovarian cancer treatment: implications of brca1/2 mutations. Cancers (Basel) 2019; 11(3)E416
[http://dx.doi.org/10.3390/cancers11030416] [PMID: 30909618]
[3]
Wilken JA, Badri T, Cross S, et al. EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem 2012; 4(4): 447-69.
[http://dx.doi.org/10.4155/fmc.12.11] [PMID: 22416774]
[4]
Franzese E, Centonze S, Diana A, et al. PARP inhibitors in ovarian cancer. Cancer Treat Rev 2019; 73: 1-9.
[http://dx.doi.org/10.1016/j.ctrv.2018.12.002] [PMID: 30543930]
[5]
Ledermann JA, Raja FA, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C. ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29(Suppl. 4): iv259.
[http://dx.doi.org/10.1093/annonc/mdy157] [PMID: 30285216]
[6]
Drew Y. The development of PARP inhibitors in ovarian cancer: from bench to bedside. Br J Cancer 2015; 113(Suppl. 1): S3-9.
[http://dx.doi.org/10.1038/bjc.2015.394] [PMID: 26669452]
[7]
Ledermann JA, Embleton AC, Raja F, et al. ICON6 collaborators. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016; 387(10023): 1066-74.
[http://dx.doi.org/10.1016/S0140-6736(15)01167-8] [PMID: 27025186]
[8]
Wiggans AJ, Cass GK, Bryant A, Lawrie TA, Morrison J. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev 2015; (5): CD007929
[http://dx.doi.org/10.1002/14651858.CD007929.pub3] [PMID: 25991068]
[9]
Jiang X, Li X, Li W, Bai H, Zhang Z. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. J Cell Mol Med 2019; 23(4): 2303-13.
[http://dx.doi.org/10.1111/jcmm.14133] [PMID: 30672100]
[10]
Yokoyama T, Kohn EC, Brill E, Lee JM. Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP. Int J Oncol 2017.
[http://dx.doi.org/10.3892/ijo.2017.3914] [PMID: 28350129]
[11]
Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin 2019; 69(4): 280-304.
[http://dx.doi.org/10.3322/caac.21559] [PMID: 31099893]
[12]
Ledermann JA. PARP inhibitors in ovarian cancer. Ann Oncol 2016; 27(Suppl. 1): i40-4.
[http://dx.doi.org/10.1093/annonc/mdw094] [PMID: 27141070]
[13]
Rust K, Spiliopoulou P, Tang CY, et al. Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real-life experience. BJOG 2018; 125(11): 1451-8.
[http://dx.doi.org/10.1111/1471-0528.15171] [PMID: 29460478]
[14]
Gori S, Barberis M, Bella MA, et al. AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group. Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. Crit Rev Oncol Hematol 2019; 140: 67-72.
[http://dx.doi.org/10.1016/j.critrevonc.2019.05.012] [PMID: 31176273]
[15]
Romeo M, Pardo JC, Martinez-Cardus A. Translational Research Opportunities Regarding Homologous Recombination in Ovarian Cancer. Int J Mol Sci 2018; 19(10): 3249.
[16]
Esashi F, Galkin VE, Yu X, Egelman EH, West SC. Stabilization of RAD51 nucleoprotein filaments by the C-terminal region of BRCA2. Nat Struct Mol Biol 2007; 14(6): 468-74.
[http://dx.doi.org/10.1038/nsmb1245] [PMID: 17515904]
[17]
Liu CH, Chang Y, Wang PH. Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer. Taiwan J Obstet Gynecol 2017; 56(5): 713-4.
[http://dx.doi.org/10.1016/j.tjog.2017.08.026] [PMID: 29037569]
[18]
Frey MK, Pothuri B. Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: A review of the literature 2017; 4: 4.
[19]
Bitler BG, Watson ZL, Wheeler LJ, Behbakht K. PARP inhibitors: Clinical utility and possibilities of overcoming resistance. Gynecol Oncol 2017; 147(3): 695-704.
[http://dx.doi.org/10.1016/j.ygyno.2017.10.003] [PMID: 29037806]
[20]
Lim JSJ, Tan DSP. Understanding resistance mechanisms and expanding the therapeutic utility of parp inhibitors. Cancers (Basel) 2017; 9(8)E109
[http://dx.doi.org/10.3390/cancers9080109] [PMID: 28829366]
[21]
Ringley JT, Moore DC, Patel J, Rose MS. Poly (adp-ribose) polymerase inhibitors in the management of ovarian cancer: A Drug Class Review P&T 2018; 43(9): 549-6.
[PMID: 30186027]
[22]
Ledermann JA, Pujade-Lauraine E. Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer. Ther Adv Med Oncol 2019. 111758835919849753
[http://dx.doi.org/10.1177/1758835919849753] [PMID: 31205507]
[23]
Plummer R. Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target. Clin Cancer Res 2010; 16(18): 4527-31.
[http://dx.doi.org/10.1158/1078-0432.CCR-10-0984] [PMID: 20823148]
[24]
Criscuolo D, Morra F, Giannella R, Cerrato A, Celetti A. Identification of novel biomarkers of homologous recombination defect in dna repair to predict sensitivity of prostate cancer cells to parp-inhibitors. Int J Mol Sci 2019; 20(12): 20.
[http://dx.doi.org/10.3390/ijms20123100] [PMID: 31242618]
[25]
Talens F, Jalving M, Gietema JA, Van Vugt MA. Therapeutic targeting and patient selection for cancers with homologous recombination defects. Expert Opin Drug Discov 2017; 12(6): 565-81.
[http://dx.doi.org/10.1080/17460441.2017.1322061] [PMID: 28425306]
[26]
Boussios S, Karathanasi A, Cooke D, et al. PARP inhibitors in ovarian cancer: the route to “ithaca”. Diagnostics (Basel) 2019; 9(2)E55
[http://dx.doi.org/10.3390/diagnostics9020055] [PMID: 31109041]
[27]
Jiang X, Li X, Li W, et al. PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. 2019; 23: 2303-13.
[28]
Matsumoto K, Nishimura M, Onoe T, et al. PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy. Jpn J Clin Oncol 2019; 49(8): 703-7.
[http://dx.doi.org/10.1093/jjco/hyz090] [PMID: 31242303]
[29]
Jiang X, Li W, Li X, Bai H, Zhang Z. Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer. Cancer Manag Res 2019; 11: 4371-90.
[http://dx.doi.org/10.2147/CMAR.S200524] [PMID: 31191001]
[30]
D’Andrea AD. Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair (Amst) 2018; 71: 172-6.
[http://dx.doi.org/10.1016/j.dnarep.2018.08.021] [PMID: 30177437]
[31]
Lok BH, Gardner EE, Schneeberger VE, et al. PARP inhibitor activity correlates with slfn11 expression and demonstrates synergy with temozolomide in small cell lung cancer. Clin Cancer Res 2017; 23(2): 523-35.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-1040] [PMID: 27440269]
[32]
Faraoni I, Graziani G. Role of brca mutations in cancer treatment with poly(adp-ribose) polymerase (parp) inhibitors. Cancers (Basel) 2018; 10(12)E487
[http://dx.doi.org/10.3390/cancers10120487] [PMID: 30518089]
[33]
Helleday T. PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations. Ann Oncol 2016; 27(5): 755-7.
[http://dx.doi.org/10.1093/annonc/mdw048] [PMID: 26865580]
[34]
Jain PG, Patel BD. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update. Eur J Med Chem 2019; 165: 198-215.
[http://dx.doi.org/10.1016/j.ejmech.2019.01.024] [PMID: 30684797]
[35]
Sehouli J, Braicu EI, Chekerov R. PARP Inhibitors for recurrent ovarian carcinoma: current treatment options and future perspectives. Geburtshilfe Frauenheilkd 2016; 76(2): 164-9.
[http://dx.doi.org/10.1055/s-0035-1558185] [PMID: 26941449]
[36]
Franzese E, Centonze S, Diana A, et al. PARP inhibitors in ovarian cancer. Cancer Treat Rev 2019; 73: 1-9.
[http://dx.doi.org/10.1016/j.ctrv.2018.12.002] [PMID: 30543930]
[37]
Matulonis UA, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer 2016; 122(12): 1844-52.
[http://dx.doi.org/10.1002/cncr.29995] [PMID: 27062051]
[38]
Kim G, Ison G, McKee AE, et al. FDA approval summary: olaparib monotherapy in patients with deleterious germline brca-mutated advanced ovarian cancer treated with three or more lines of chemotherapy. Clin Cancer Res 2015; 21(19): 4257-61.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-0887] [PMID: 26187614]
[39]
Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014; 15(8): 852-61.
[http://dx.doi.org/10.1016/S1470-2045(14)70228-1] [PMID: 24882434]
[40]
Liu JF, Barry WT, Birrer M, et al. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol 2019; 30(4): 551-7.
[http://dx.doi.org/10.1093/annonc/mdz018] [PMID: 30753272]
[41]
Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018; 379(26): 2495-505.
[http://dx.doi.org/10.1056/NEJMoa1810858] [PMID: 30345884]
[42]
Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010; 28(15): 2512-9.
[http://dx.doi.org/10.1200/JCO.2009.26.9589] [PMID: 20406929]
[43]
Pujade-Lauraine E, Ledermann JA, Selle F, et al. SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017; 18(9): 1274-84.
[http://dx.doi.org/10.1016/S1470-2045(17)30469-2] [PMID: 28754483]
[44]
Gunderson CC, Erickson BK, Buechel ME, Moore KN. The current landscape of parp inhibitors in ovarian cancer. Curr Obstet Gynecol Rep 2018; 7: 20-7.
[http://dx.doi.org/10.1007/s13669-018-0233-7]
[45]
Oza AM, Cibula D, Benzaquen AO, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol 2015; 16(1): 87-97.
[http://dx.doi.org/10.1016/S1470-2045(14)71135-0] [PMID: 25481791]
[46]
Hirte H, Lheureux S, Fleming GF, et al. A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia. Gynecol Oncol 2015; 138(1): 55-61.
[http://dx.doi.org/10.1016/j.ygyno.2015.04.009] [PMID: 25895616]
[47]
Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol 2009; 27(33): 5601-6.
[http://dx.doi.org/10.1200/JCO.2009.23.2777] [PMID: 19826113]
[48]
Liu JF, Barry WT, Birrer M, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol 2014; 15(11): 1207-14.
[http://dx.doi.org/10.1016/S1470-2045(14)70391-2] [PMID: 25218906]
[49]
Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015; 33(3): 244-50.
[http://dx.doi.org/10.1200/JCO.2014.56.2728] [PMID: 25366685]
[50]
Syed YY. Rucaparib: First global approval. Drugs 2017; 77(5): 585-92.
[http://dx.doi.org/10.1007/s40265-017-0716-2] [PMID: 28247266]
[51]
Colombo I, Lheureux S, Oza AM. Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer. Drug Des Devel Ther 2018; 12: 605-17.
[http://dx.doi.org/10.2147/DDDT.S130809] [PMID: 29606854]
[52]
Swisher EM, Lin KK, Oza AM, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 2017; 18(1): 75-87.
[http://dx.doi.org/10.1016/S1470-2045(16)30559-9] [PMID: 27908594]
[53]
Coleman RL, Oza AM, Lorusso D, et al. ARIEL3 investigators. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 390(10106): 1949-61.
[http://dx.doi.org/10.1016/S0140-6736(17)32440-6] [PMID: 28916367]
[54]
Kristeleit R, Shapiro GI, Burris HA, et al. A phase i-ii study of the oral parp inhibitor rucaparib in patients with germline brca1/2-mutated ovarian carcinoma or other solid tumors. Clin Cancer Res 2017; 23(15): 4095-106.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-2796] [PMID: 28264872]
[55]
Mirza MR, Monk BJ, Herrstedt J, et al. ENGOT-OV16/NOVA investigators. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 2016; 375(22): 2154-64.
[http://dx.doi.org/10.1056/NEJMoa1611310] [PMID: 27717299]
[56]
Konstantinopoulos PA, Waggoner S, Vidal GA, et al. Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. JAMA Oncol 2019.
[http://dx.doi.org/10.1001/jamaoncol.2019.1048] [PMID: 31194228]
[57]
Musella A, Bardhi E, Marchetti C, et al. Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer. Cancer Treat Rev 2018; 66: 7-14.
[http://dx.doi.org/10.1016/j.ctrv.2018.03.004] [PMID: 29605737]
[58]
Shen Y, Rehman FL, Feng Y, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res 2013; 19(18): 5003-15.
[http://dx.doi.org/10.1158/1078-0432.CCR-13-1391] [PMID: 23881923]
[59]
de Bono J, Ramanathan RK, Mina L, et al. Phase i, dose-escalation, two-part trial of the parp inhibitor talazoparib in patients with advanced germline brca1/2 mutations and selected sporadic cancers. Cancer Discov 2017; 7(6): 620-9.
[http://dx.doi.org/10.1158/2159-8290.CD-16-1250] [PMID: 28242752]
[60]
Aoyagi-Scharber M, Gardberg AS, Yip BK, Wang B, Shen Y, Fitzpatrick PA. Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone. Acta Crystallogr F Struct Biol Commun 2014; 70(Pt 9): 1143-9.
[http://dx.doi.org/10.1107/S2053230X14015088] [PMID: 25195882]
[61]
Murai J, Huang SY, Renaud A, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther 2014; 13(2): 433-43.
[http://dx.doi.org/10.1158/1535-7163.MCT-13-0803] [PMID: 24356813]
[62]
Donawho CK, Luo Y, Luo Y, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007; 13(9): 2728-37.
[http://dx.doi.org/10.1158/1078-0432.CCR-06-3039] [PMID: 17473206]
[63]
Mittica G, Ghisoni E, Giannone G, et al. PARP inhibitors in ovarian cancer. Recent Patents Anticancer Drug Discov 2018; 13(4): 392-410.
[http://dx.doi.org/10.2174/1574892813666180305165256] [PMID: 29512470]
[64]
Thomas A, Murai J, Pommier Y. The evolving landscape of predictive biomarkers of response to PARP inhibitors. J Clin Invest 2018; 128(5): 1727-30.
[http://dx.doi.org/10.1172/JCI120388] [PMID: 29664016]
[65]
Coleman RL, Sill MW, Bell-McGuinn K, et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2015; 137(3): 386-91.
[http://dx.doi.org/10.1016/j.ygyno.2015.03.042] [PMID: 25818403]
[66]
Ohmoto A, Yachida S. Current status of poly(ADP-ribose) polymerase inhibitors and future directions. OncoTargets Ther 2017; 10: 5195-208.
[http://dx.doi.org/10.2147/OTT.S139336] [PMID: 29138572]
[67]
Steffensen KD, Adimi P, Jakobsen A. Veliparib monotherapy to patients with brca germ line mutation and platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer: a phase i/ii study. Int J Gynecol Cancer 2017; 27(9): 1842-9.
[http://dx.doi.org/10.1097/IGC.0000000000001089] [PMID: 28763368]
[68]
Gray HJ, Bell-McGuinn K, Fleming GF, et al. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecol Oncol 2018; 148(3): 507-14.
[http://dx.doi.org/10.1016/j.ygyno.2017.12.029] [PMID: 29352572]
[69]
Martin GA, Chen AH, Parikh K. A novel use of olaparib for the treatment of metastatic castration-recurrent prostate cancer. Pharmacotherapy 2017; 37(11): 1406-14.
[http://dx.doi.org/10.1002/phar.2027] [PMID: 28895177]
[70]
Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline brca-mutated metastatic pancreatic cancer. N Engl J Med 2019; 381(4): 317-27.
[http://dx.doi.org/10.1056/NEJMoa1903387] [PMID: 31157963]
[71]
Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline brca mutation. N Engl J Med 2018; 379(8): 753-63.
[http://dx.doi.org/10.1056/NEJMoa1802905] [PMID: 30110579]
[72]
Norquist B, Wurz KA, Pennil CC, et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 2011; 29(22): 3008-15.
[http://dx.doi.org/10.1200/JCO.2010.34.2980] [PMID: 21709188]
[73]
Barber LJ, Sandhu S, Chen L, et al. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol 2013; 229(3): 422-9.
[http://dx.doi.org/10.1002/path.4140] [PMID: 23165508]
[74]
Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008; 451(7182): 1111-5.
[http://dx.doi.org/10.1038/nature06548] [PMID: 18264088]
[75]
Issaeva N, Thomas HD, Djureinovic T, et al. 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res 2010; 70(15): 6268-76.
[http://dx.doi.org/10.1158/0008-5472.CAN-09-3416] [PMID: 20631063]
[76]
McCormick A, Donoghue P, Dixon M, et al. Ovarian cancers harbor defects in nonhomologous end joining resulting in resistance to rucaparib. Clin Cancer Res 2017; 23(8): 2050-60.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-0564] [PMID: 27702817]
[77]
Makvandi M, Xu K, Lieberman BP, et al. A radiotracer strategy to quantify parp-1 expression in vivo provides a biomarker that can enable patient selection for parp inhibitor therapy. Cancer Res 2016; 76(15): 4516-24.
[http://dx.doi.org/10.1158/0008-5472.CAN-16-0416] [PMID: 27261505]
[78]
Lord CJ, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med 2013; 19(11): 1381-8.
[http://dx.doi.org/10.1038/nm.3369] [PMID: 24202391]
[79]
Jaspers JE, Kersbergen A, Boon U, et al. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov 2013; 3(1): 68-81.
[http://dx.doi.org/10.1158/2159-8290.CD-12-0049] [PMID: 23103855]
[80]
Gilardini Montani MS, Prodosmo A, Stagni V, et al. ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition. J Exp Clin Cancer Res 2013; 32: 95.
[http://dx.doi.org/10.1186/1756-9966-32-95] [PMID: 24252502]
[81]
Choi YH, Yu AM. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des 2014; 20(5): 793-807.
[http://dx.doi.org/10.2174/138161282005140214165212] [PMID: 23688078]
[82]
Xu G, Chapman JR, Brandsma I, et al. REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature 2015; 521(7553): 541-4.
[http://dx.doi.org/10.1038/nature14328] [PMID: 25799992]
[83]
Bang YJ, Im SA, Lee KW, et al. Randomized, double-blind phase ii trial with prospective classification by atm protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer. J Clin Oncol 2015; 33(33): 3858-65.
[http://dx.doi.org/10.1200/JCO.2014.60.0320] [PMID: 26282658]
[84]
Murai J, Huang SY, Das BB, et al. Trapping of parp1 and parp2 by clinical parp inhibitors. Cancer Res 2012; 72(21): 5588-99.
[http://dx.doi.org/10.1158/0008-5472.CAN-12-2753] [PMID: 23118055]
[85]
Sander Effron S, Makvandi M, Lin L, et al. PARP-1 expression quantified by [18f]fluorthanatrace: a biomarker of response to parp inhibition adjuvant to radiation therapy. Cancer Biother Radiopharm 2017; 32(1): 9-15.
[http://dx.doi.org/10.1089/cbr.2016.2133] [PMID: 28118040]
[86]
Wysham WZ, Mhawech-Fauceglia P, Li H, et al. BRC Aness profile of sporadic ovarian cancer predicts disease recurrence. PLoS One 2012; 7(1)e30042
[http://dx.doi.org/10.1371/journal.pone.0030042] [PMID: 22253870]
[87]
Choi YE, Meghani K, Brault ME, et al. Platinum and parp inhibitor resistance due to overexpression of microrna-622 in brca1-mutant ovarian cancer. Cell Rep 2016; 14(3): 429-39.
[http://dx.doi.org/10.1016/j.celrep.2015.12.046] [PMID: 26774475]
[88]
Meghani K, Fuchs W, Detappe A, et al. Multifaceted impact of microrna 493-5p on genome-stabilizing pathways induces platinum and parp inhibitor resistance in brca2-mutated carcinomas. Cell Rep 2018; 23(1): 100-11.
[http://dx.doi.org/10.1016/j.celrep.2018.03.038] [PMID: 29617652]
[89]
Pettitt SJ, Rehman FL, Bajrami I, et al. A genetic screen using the piggybac transposon in haploid cells identifies parp1 as a mediator of olaparib toxicity. PLoS One 2013; 8(4)e61520
[http://dx.doi.org/10.1371/journal.pone.0061520] [PMID: 23634208]
[90]
Binkhathlan Z, Lavasanifar A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr Cancer Drug Targets 2013; 13(3): 326-46.
[http://dx.doi.org/10.2174/15680096113139990076] [PMID: 23369096]
[91]
Choi YE, Battelli C, Watson J, et al. Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells. Oncotarget 2014; 5(9): 2678-87.
[http://dx.doi.org/10.18632/oncotarget.1929] [PMID: 24798692]
[92]
Parsels LA, Karnak D, Parsels JD, et al. PARP1 trapping and dna replication stress enhance radiosensitization with combined wee1 and parp inhibitors. Mol Cancer Res 2018; 16(2): 222-32.
[http://dx.doi.org/10.1158/1541-7786.MCR-17-0455] [PMID: 29133592]
[93]
Saldivar JC, Hamperl S, Bocek MJ, Chung M. An intrinsic S/G2 checkpoint enforced by ATR. 2018; 361: 806-10.
[94]
Haynes B, Murai J, Lee JM. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition. Cancer Treat Rev 2018; 71: 1-7.
[http://dx.doi.org/10.1016/j.ctrv.2018.09.003] [PMID: 30269007]
[95]
Fang Y, McGrail DJ, Sun C, et al. Sequential therapy with parp and wee1 inhibitors minimizes toxicity while maintaining efficacy. Cancer Cell 2019; 35(6): 851-867.e7.
[http://dx.doi.org/10.1016/j.ccell.2019.05.001] [PMID: 31185210]
[96]
Garcia TB, Snedeker JC, Baturin D, et al. A small-molecule inhibitor of wee1, azd1775, synergizes with olaparib by impairing homologous recombination and enhancing dna damage and apoptosis in acute leukemia. Mol Cancer Ther 2017; 16(10): 2058-68.
[http://dx.doi.org/10.1158/1535-7163.MCT-16-0660] [PMID: 28655785]
[97]
Buisson R, Niraj J, Rodrigue A, et al. Coupling of homologous recombination and the checkpoint by atr. Mol Cell 2017; 65(2): 336-46.
[http://dx.doi.org/10.1016/j.molcel.2016.12.007] [PMID: 28089683]
[98]
Dréan A, Williamson CT, Brough R, et al. Modeling therapy resistance in brca1/2-mutant cancers. Mol Cancer Ther 2017; 16(9): 2022-34.
[http://dx.doi.org/10.1158/1535-7163.MCT-17-0098] [PMID: 28619759]
[99]
Geenen JJJ, Schellens JHM. Molecular pathways: targeting the protein kinase wee1 in cancer. Clin Cancer Res 2017; 23(16): 4540-4.
[http://dx.doi.org/10.1158/1078-0432.CCR-17-0520] [PMID: 28442503]
[100]
Kim H, George E, Ragland R, et al. Targeting the atr/chk1 axis with parp inhibition results in tumor regression in brca-mutant ovarian cancer models. Clin Cancer Res 2017; 23(12): 3097-108.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-2273] [PMID: 27993965]
[101]
Johnson SF, Cruz C, Greifenberg AK, et al. CDK12 inhibition reverses de novo and acquired parp inhibitor resistance in brca wild-type and mutated models of triple-negative breast cancer. Cell Rep 2016; 17(9): 2367-81.
[http://dx.doi.org/10.1016/j.celrep.2016.10.077] [PMID: 27880910]
[102]
Alagpulinsa DA, Ayyadevara S, Yaccoby S, Shmookler Reis RJ. A cyclin-dependent kinase inhibitor, dinaciclib, impairs homologous recombination and sensitizes multiple myeloma cells to parp inhibition. Mol Cancer Ther 2016; 15(2): 241-50.
[http://dx.doi.org/10.1158/1535-7163.MCT-15-0660] [PMID: 26719576]
[103]
Bajrami I, Frankum JR, Konde A, et al. Genome-wide profiling of genetic synthetic lethality identifies cdk12 as a novel determinant of parp1/2 inhibitor sensitivity. Cancer Res 2014; 74(1): 287-97.
[http://dx.doi.org/10.1158/0008-5472.CAN-13-2541] [PMID: 24240700]
[104]
Jiao S, Xia W, Yamaguchi H, et al. PARP inhibitor upregulates pd-l1 expression and enhances cancer-associated immunosuppression. Clin Cancer Res 2017; 23(14): 3711-20.
[http://dx.doi.org/10.1158/1078-0432.CCR-16-3215] [PMID: 28167507]
[105]
Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 2014; 32(13): 1302-8.
[http://dx.doi.org/10.1200/JCO.2013.51.4489] [PMID: 24637997]
[106]
Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012; 30(17): 2039-45.
[http://dx.doi.org/10.1200/JCO.2012.42.0505] [PMID: 22529265]
[107]
Bayraktar S, Arun B. BRCA mutation genetic testing implications in the United States. Breast 2017; 31: 224-32.
[http://dx.doi.org/10.1016/j.breast.2016.11.021] [PMID: 27931006]